(E)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (E)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
• 化学式: C12H15N3O4
• 分子量: 265.26
• InChiKey: QKTRIGNWBRHBFV-DUXPYHPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  82.5
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX
  申请人：THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate

  公开号：US20150251987A1

  公开（公告）日：2015-09-10

  Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

  提供了用于治疗Toll样受体1/2复合物（TLRI/2）相关炎症性疾病的化合物、组合物和方法。公开了基于苯并三环酮支架的小分子，能够影响下游信号传导，以及制备和修改这些分子的方法。还提供了用于治疗与Toll样受体复合物1/2激活相关的临床状况的方法，包括向受试者施用有效量的苯并三环酮化合物。
• Compound for anti-cancer therapy that acts by targeting GOF mutant P53 and stimulates P73 to restore the P53 pathway signaling
  申请人：The Penn State Research Foundation

  公开号：US10322123B2

  公开（公告）日：2019-06-18

  The invention includes compositions comprising NSC59984 or a derivative or analog thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

  本发明包括包含 NSC59984 或其衍生物或类似物以及药学上可接受的载体的组合物。本发明还包括治疗或预防受试者癌症的方法，包括向受试者施用本发明所述组合物的步骤。
• Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling
  申请人：The Penn State Research Foundation

  公开号：US10744133B2

  公开（公告）日：2020-08-18

  The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

  本发明包括包含 NSC59984 或其衍生物或类似物以及药学上可接受的载体的组合物。本发明还包括治疗或预防受试者癌症的方法，包括向受试者施用本发明所述组合物的步骤。
• EP3200794A1
  申请人：——

  公开号：EP3200794A1

  公开（公告）日：2017-08-09
• METHODS OF TREATING CANCER
  申请人：Kartos Therapeutics, Inc.

  公开号：EP3787625A1

  公开（公告）日：2021-03-10